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Results: The pharmacovigilance program involved 1 general hos-
pital (Ass.2 ‘Isontina’, Gorizia-Italy), 12 pharmacies, and 24 GPs. 
From March 2012 to March 2013, Medigenia enrolled 2074 patients 
(52.4% women; mean age, 69 [8]).The system totally administered 
62,499 drugs (68.2% prescriptions, 28.4% OTC, and 3.4% herbs), 
and 3028 were the DDIs identified among them. GPs received 2738 
alerts for ADR risk (48% moderate risk, 23.2% high risk): treat-
ment was changed 871 times (31.8%).The most frequent alert among 
high risk connected with hemorrhage (87.6%), involving primarily 
acetyl-salicylic acid and warfarin. Moderate risk concerned mainly 
neurologic sequels (38.2%) and involved in particular antineoplastic 
agents and phenytoin.
Conclusion: People taking drugs are not always aware of the health 
risk they are going toward after a multidrug therapy or simply tak-
ing a medicine without asking GP, a trend that is increasing in the 
last years. Medigenia prevents ADR and their health sequels using a 
cloud-based approach for pharmacovigilance.
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Introduction: Drug-induced liver injury (DILI) is the most fre-
quent reason for withdrawal of approved drugs from the market 
and accounts for 7% to 15% of the cases of acute liver failure in 
Europe and the United States. The risk of developing hepatotoxic-
ity involves a complex interplay between the chemical properties of 
the drug, environment factors, age, sex, underlying diseases, and 
genetic factors.
Patients (or Materials) and Methods: OBJECTIVES: To determinate 
the incidence of DILI detected through a pharmacovigilance program 
from laboratory signals in hospitalized patients in La Paz University 
Hospital from July 2007 to December 2010. Secondary objectives: 
(1) characterize patients with DILI; (2) determinate suspected drugs 
of DILI according to therapeutic group; and (3) classification of cases 
according to type of lesion.
Methods: All serum alanine transaminase (ALT) and aspartate 
transaminase (AST) > 3 upper limit normality (ULN) or > 2 ULN 
of gamma glutamil transpeptidasa (GGT) or bilirubin, detected at 
admission to the hospital, including those patients who died in the 
emergency ward or during hospitalization, were monitored prospec-
tively from July 2007 through December 2010. We evaluated each 
patient to assess alternative causes or confirm DILI. The incidence 
was calculated by dividing the number of cases by the number of 
hospitalizations in that period.
Results: We detected 2490 cases of liver enzyme disorders in the 
study period, with an incidence of 146 cases per 10,000 inpatients 
(Poisson 95% CI, 123.3–171.1). Of these, 198 cases (7.95%) were 
secondary to drugs, reporting an incidence of 11.6 cases of DILI 
per 10,000 inpatients (Poisson 95% CI, 6.2–19.7). The median of 
age was 47.6 (24.4) years, and 49.6% were female. Most of the 
DILI (64.6%) occurred during hospitalization and the rest were out-
patients. The hospitalization wards with more cases of DILI were 
Hematology and Internal Medicine (15.7% each one). The main ther-
apeutic groups of suspected drugs of DILI in our study according to 
the ATC classification system were: J. Antiinfectives for systemic use 
(34.1%), L. Antineoplastic and immunomodulating agents (20.1%) 
and N. Nervous system (18.6%). The classification according to the 
type of lesion: 52.5% was cholestatic, 32.3% had hepatocellular 
injury, and 15.2% had mix pattern. The median (range) of ALT level 
was 656.4 (31–14,397 UI/L); AST, 619.8 (12–17,671 UI/L); GGT, 
420.6 (14–5708 UI/L); and BT, 2.11 (0.1–38.2 mg/dL).
Conclusion: (1) One case of 11 inpatients with liver enzyme disor-
ders is drug-induced. (2) Most of DILI occur during hospitalization. 
(3) The main drugs associated with DILI are antibiotics included in 
group J of the ATC classification system.
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Introduction: The assessment of the adverse drug reactions risk is 
an important factor in drug safety monitoring system. The aim of 
our study was to assess knowledge and attitudes of pharmacologi-
cally educated and pharmacologically noneducated students from the 
University of Montenegro regarding drug safety risk.
Patients (or Materials) and Methods: In this cross-sectional study, a 
self-completion questionnaire was delivered to 63 pharmacologically 
educated students (medical students who attended Pharmacology 
course and passed exams within it), 50 pharmacologically nonedu-
cated students (medical students who attended Pharmacology course 
but did not pass exams within it), and 50 students from other non-
medical faculties at the University of Montenegro.
Results: As expected, pharmacologically educated students are 
considered to be better informed about ADRs than other partici-
pants (P < 0.01). Prescription drugs were ranked as less dangerous 
than self-medication by all participants. Anticoagulants were con-
sidered the most dangerous drugs by pharmacologically educated 
students (median, 7.5; scale, 1–10; interquartile range, 3.75–8), 
and antidepressants, anxiolytics, and hypnotics by pharmacologi-
cally noneducated students (median, 8, all). Information about drug 
safety significantly influenced the choice of therapy by both groups 
of students questioned (median, 8–10, all).
Conclusion: On the basis of the aforementioned results, it can be 
concluded that when risk of adverse drug reactions is in question, 
pharmacologically educated students are much better informed than 
pharmacologically noneducated medical students and students from 
nonmedical faculties. Additional educational efforts are necessary to 
build awareness among general population of adverse drug reactions.
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Introduction: The knowledge of frequency, character, severity, and 
other peculiarities of adverse reactions (ADR) as well as of dynamic 
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of their changes in comparison with previous years is very important 
for effective pharmacovigilance (PV) (eg, taking of regulatory acts, 
update of instructions for use, revealing of medical mistakes).
Patients (or Materials) and Methods: To analyze structure of ADR, 
we used search in ARCADe (Adverse Reactions in Crimea Autonomy 
DatabasE).
Results: In 2012, Regional PV office of State Expert Center of 
Ukraine in Simferopol (Crimea Autonomic Republic) received 1135 
spontaneous reports about ADR from 123 hospitals. As in 2006-
2011 period, most frequently ADR were registered in 1-st year 
children (98 cases) and 46 to 60 year-old adults (259). Sixty-five 
percent of reports informed about ADR in females, 35% in males. 
Two reactions were lethal (both in children, uncertain causality), 72 
were life-threating, 102 resulted in hospitalization of patient, and 
181 in temporary disability. Most of drugs were used per os (575), 
others were prescribed intramuscularly (190), intravenously (239), 
or in topical forms (69 reports). A total of 133 patients had allergy 
in anamnesis, 73 from them had medicinal allergy. A total of 328 
patients took only 1 product (monotherapy), when other took com-
binations of drugs, from them 113 patients 5 medicines and more. 
Most frequently drugs were prescribed for treatment of respiratory 
diseases (269), heart diseases (176), and infections (148). A total of 
563 reports informed about skin rush, 115 about dyspeptic disorders, 
96 about central neural system symptoms, 53 about fever, 53 about 
hemopoiesis depression, 37 and 15 about angioneurotic edema and 
anaphylactic shock, respectively. In 71%, ADRs needed medical cor-
rection–prescription of additional drugs. The structure of ADR data 
according to groups is following: 41% of reactions were caused by 
systemic antimicrobial agents (ATC J01-J07), 12% by cardiovascular 
drugs (C01-C10), 8.3% by drugs influencing on CNS, and 7.5% by 
nonsteroidal anti-inflammatory drugs. The top 3 of products use of 
which resulted in ADR includes: ceftriaxone (62 cases), zidovudine/
lamivudine combination (52 cases), and ceftazidime (37 cases).
The most frequent errors found during analysis were ignoring of 
allergic anamnesis, off-label use (ignoring of age limits, pregnancy, 
lactation, contraindications), overdosage, and breaches of treatment 
regimen.
Conclusion: Regular analysis of ADR data received from doctors 
allows to define specific patterns of reactions development, phar-
macologic groups of high risk of complications and most frequent 
medical errors. Knowledge of them let clinical pharmacologists, regu-
latory agency, and educational societies to focus on the issues really 
important for effective and safe pharmacotherapy.
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Introduction: Drug-associated acute liver injury is a common con-
cern in drug safety, especially acute liver failure leading to registration 
for transplantation (ALFT). SALT was designed to explore drug-
associated ALFT.
Patients (or Materials) and Methods: French ALFT cases exposed 
to drugs within 30 days of first symptoms were compared with 
drug utilization data from the 1/97 sample of the French National 
Healthcare database (EGB). Event rates were computed per billion 
DDD dispensed over the period and per million users, compared 
with the average number of DDD dispensed per user over 3 years. 
Chronic liver disease, documented clinical causes, and drug overdoses 
were excluded.
Results: The 65 cases of ALFT identified in France (2005-2007) had 
been exposed to 235 different drugs. The drug classes most found 
were paracetamol (47 cases), anxiolytics (n = 13), antiepileptic drugs 
(n = 11), NSAIDs (n = 10), H1 antihistamines (n = 8), proton pump 
inhibitors (n = 7), and antidepressants (n = 6). Other classes were 
associated with ≤5 cases. Rates ranged from 1.9 (bromazepam) to 
372 cases per billion DDD (prazepam). Per user rates ranged from 
0.19 (pantoprazole) to 56 per million (phenytoin). For NSAIDs, PPI, 
and some H1 antagonists, event rates decreased with increasing aver-
age number of DDD dispensed. In these classes, the event rate per 
user was below 1 per million users. For other drug classes such as 
antiepileptic drugs, the event rates per billion DDD were similar, and 
rates per million users increased with increasing average number of 
DDD dispensed per subject. Drugs fell into 3 main categories: event 
rates below 1 per million users (NSAIDs, PPI, most antihistamines, 
some benzodiazepines), from 1 to 10 per million users (paracetamol, 
benzodiazepines, antiepileptic drugs), and above 10 per million users. 
Antidepressants were ~1 case per million users. Two antiepileptic 
drugs had event rates at or above 10 per million users. Overall, drugs 
with longer duration of use tended to have higher per user event rates.
Conclusion: These results are still tentative because of the small num-
ber of cases for individual drugs. SALT should be extended.
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Introduction: In South Africa, mental health services are underre-
sourced, and management of psychiatric disorders is poorly inte-
grated into the primary health care system. Despite the statistic that 
neuropsychiatric disorders are ranked third in the national burden 
of disease (following HIV/AIDS and the category “other infectious 
diseases”), little has been done to document the current services to 
improve mental healthcare systems. The aim of this research, there-
fore, was to establish a baseline of antidepressant utilization in vari-
ous sectors of health service offered in Gauteng, South Africa’s most 
populous province. This particular segment reports on antidepressant 
usage in a sample of dispensing doctors prescriptions in 2 geographic 
locations in Gauteng.
Patients (or Materials) and Methods: Two datasets (A and B) 
were acquired from different medical data warehousing compa-
nies. Each dataset comprised 1 years’ medical records from health 
care practitioners subscribed to the respective company (Dataset A 
from 2009, Dataset B from 2011). Data included a unique patient 
number, age, gender, treatment code, ICD-10 code, and treatment 
date. Microsoft Excel was used to filter the data and isolate patients 
treated with an antidepressant and a cluster analysis performed to 
group antidepressants together. Simple descriptive statistics were 
determined. Data were analyzed using STATA (v10.0). Statistical 
significance was determined using Pearson’s chi-squared tests, Mann 
Whitney U test, and logistic regression. Significance levels were set 
at P < 0.05.
